Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.8 USD | +0.08% | -4.28% | -15.99% |
05-10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
05-08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.99% | 1.17B | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals Shares Fall After Disappointing Data From Phase 2B Study for Biliary Atresia